Cromos Pharma delivering clinical trial success in breast cancer studies

As Breast Cancer Awareness Month 2021 comes to an end, Cromos Pharma is pleased to share its experience with successful breast cancer clinical studies. This article outlines Cromos Pharma’s strong track record working with top international pharma and biotech sponsors on breast cancer studies.

Over 16 years delivering clinical trial success in breast cancer studies

At Cromos Pharma, our first clinical research project was conducted in breast cancer. Since 2004, we have conducted dozens of trials involving thousands of breast cancer patients.

  • 10+ Phase II/III studies
  • 250+ sites
  • 3,000+ patients enrolled

These studies have focused on a range of areas from finding innovative targeted therapies, to biosimilar and generic studies, aimed at offering wider access to novel treatments. In 2019, our team successfully recruited almost 500 patients (92% of total) for a multi-country breast cancer study in just seven months.

Cromos Pharma’s flexible oncology model

Cromos Pharma offers a flexible oncology model focused on optimized study design combined with rapid patient  enrollment, to accelerate high quality data results.

 Cromos Pharma offers a flexible, tailored and scalable model focused on:

  • Optimized study design
  • In-depth regulatory expertise across our regions
  • Faster start-up timelines
  • Rapid patient enrollment
  • High quality data

Cromos Pharma works on breast cancer studies for international and regional pharma, as well as biotech companies, including the 3 of the top 10 pharma companies (Roche, Novartis and Pfizer) in the world.

According to the World Health Organization (WHO), breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. It accounts for 25% of all cases of female cancers. 2.3 million women were diagnosed with breast cancer and 700,000 deaths were caused by breast cancer globally in 2020. Significant progress has been made in recent years in the treatment of breast cancer, which has helped reduce mortality. In high-income countries like the US, breast cancer mortality rates have decreased  to less than 15%. However, in lower income countries in Eastern Europe, Asia, Africa, and South America, despite lower incidence rates, the mortality rates remain as high as 50% or more, and represent 58% of global mortality.

About Cromos Pharma

Cromos Pharma is a US-based international contract research organization with 16 years’ experience in delivering fully integrated clinical research solutions, in all trial phases, across a wide range of therapeutic areas. Our expert team boasts wide-ranging expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management.

From studies in biosimilars and generics to successfully managing oncology, neurology, and dermatology clinical trials, our team provides full service solutions to international pharma and biotech in high recruiting regions, with high quality data assured.

Established in 2004, Cromos Pharma has strong regional experience in Central and Eastern Europe, supported by an extensive network of offices. Its international HQ is in Portland, Oregon, USA.

Contact bd@cromospharma.com to arrange a meeting with our team to discuss your next clinical project.

CONTACT

BD@CROMOSPHARMA.COM

To arrange an introductory meeting and find out how our experience can benefit your next clinical project.